Cargando…

Empowering Clinical Diagnostics with Mass Spectrometry

[Image: see text] The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS...

Descripción completa

Detalles Bibliográficos
Autor principal: Banerjee, Shibdas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016904/
https://www.ncbi.nlm.nih.gov/pubmed/32064364
http://dx.doi.org/10.1021/acsomega.9b03764
_version_ 1783497082689028096
author Banerjee, Shibdas
author_facet Banerjee, Shibdas
author_sort Banerjee, Shibdas
collection PubMed
description [Image: see text] The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS-based in vitro diagnostics are already adopted in routine clinical practices, more are expected to undergo transition from bench to bedside in the near future. The ultrahigh sensitivity, specificity, and low turnaround time in molecular detection by MS make this technology highly powerful in disease detection and therapy monitoring. This mini-review highlights how MS has created a new paradigm in clinical diagnosis, which is growing in importance for public health.
format Online
Article
Text
id pubmed-7016904
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-70169042020-02-14 Empowering Clinical Diagnostics with Mass Spectrometry Banerjee, Shibdas ACS Omega [Image: see text] The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS-based in vitro diagnostics are already adopted in routine clinical practices, more are expected to undergo transition from bench to bedside in the near future. The ultrahigh sensitivity, specificity, and low turnaround time in molecular detection by MS make this technology highly powerful in disease detection and therapy monitoring. This mini-review highlights how MS has created a new paradigm in clinical diagnosis, which is growing in importance for public health. American Chemical Society 2020-01-30 /pmc/articles/PMC7016904/ /pubmed/32064364 http://dx.doi.org/10.1021/acsomega.9b03764 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Banerjee, Shibdas
Empowering Clinical Diagnostics with Mass Spectrometry
title Empowering Clinical Diagnostics with Mass Spectrometry
title_full Empowering Clinical Diagnostics with Mass Spectrometry
title_fullStr Empowering Clinical Diagnostics with Mass Spectrometry
title_full_unstemmed Empowering Clinical Diagnostics with Mass Spectrometry
title_short Empowering Clinical Diagnostics with Mass Spectrometry
title_sort empowering clinical diagnostics with mass spectrometry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016904/
https://www.ncbi.nlm.nih.gov/pubmed/32064364
http://dx.doi.org/10.1021/acsomega.9b03764
work_keys_str_mv AT banerjeeshibdas empoweringclinicaldiagnosticswithmassspectrometry